| |
| Issue |
Title |
| |
| Vol 12, No 2 (2024) |
Genetic features of a patient may influence the efficacy and safety profile of a medicinal product |
Abstract
PDF (Rus)
|
|
D. A. Sychev |
| |
| Vol 12, No 1 (2024) |
“Implementing the pharmacovigilance system and publishing this journal, we were helping healthcare providers cultivate the sense of professional and civic responsibility” |
Abstract
PDF (Rus)
|
|
V. K. Lepakhin, A. V. Astakhova |
| |
| Vol 11, No 4 (2023) |
Artificial Intelligence Can Bring Tens of Trillions of Rubles to the Pharmaceutical Industry |
Abstract
PDF (Rus)
|
|
A. V. Pogrebnyak |
| |
| Vol 11, No 3 (2023) |
Transition to the Non-Clinical Drug Development Principles and Rules of the Eurasian Economic Union: Changes, Challenges, and Prospects |
Abstract
PDF (Rus)
|
|
A. A. Spasov |
| |
| Vol 11, No 2 (2023) |
Conducting Pharmaceutical Inspections in the Russian Federation to Ensure Compliance with the EAEU GCP Requirements Is an Accepted Necessity |
Abstract
PDF (Rus)
|
|
A. A. Trapkova |
| |
| Vol 11, No 1 (2023) |
New Edition of the EAEU Good Pharmacovigilance Practice: What Has Changed? |
Abstract
PDF (Rus)
|
|
D. A. Rozhdestvensky |
| |
| Vol 10, No 4 (2022) |
Vladimir Chulanov: “Our experience with overcoming the pandemic will help us effectively address future threats” |
Abstract
PDF (Rus)
|
|
article Editorial |
| |
| 1 - 7 of 7 Items |
|
